U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07122882) titled 'Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance' on Aug. 08.
Brief Summary: Currently, tyrosine kinase inhibitor (TKI) remains the standard of care for oncogene-driven non-small cell lung cancer (NSCLC). However, almost all oncogene-driven NSCLCs would develop acquired resistance against TKI in clinical practice. Therefore, understanding the molecular mechanisms underlying the acquired resistance is a critical issue in lung cancer. Based on the literature, acquired resistance mechanism against EGFR TKI includes EGFR secondary mutation (T790M, C797X, L792X, G796X, L718Q, and exon 20 insertions), MET amplificatio...